MGC Pharmaceuticals Limited MGC Pharma Investor Presentation -12/02/2021
09 Febbraio 2021 - 9:02AM
RNS Non-Regulatory
TIDMMXC
MGC Pharmaceuticals Limited
09 February 2021
9 February MGC Pharma Investor Presentation - Friday 12th February
2021 2021
ASX Code:
MXC
LSE Code:
MXC
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC, 'MGC Pharma' or
'the Company'), a European based and dual listed bio-pharma company
specialising in the production and development of
phytocannabinoid-derived medicines, is pleased to announce that
Roby Zomer, CEO and Managing Director, and Brett Mitchell,
Executive Chairman, will be presenting at an investor webinar being
hosted jointly by Turner Pope Investments and Vox Markets.
MGC Pharma is the first medicinal cannabis company to be listed
on the LSE.
The webinar will take place at 10am GMT (9pm Sydney) on Friday
12th February 2021. Please register your interest at
https://voxmarkets.brand.live/c/vox-markets-and-turner-pope-webinar-friday-february-12th
.
--Ends--
For further information please contact:
UK PR Tavistock - Tavistock MGC Pharmaceuticals Ltd
Charlies Vivian +44 20 7920 3150 Roby Zomer
Charles.Vivian@tavistock.co.uk CEO & Managing Director
+61 8 6382 3390
PR/IR Advisors - Media & Capital info@mgcpharma.com.au
Partners
Rod Hinchcliffe (IR) +61 412 277 Corporate Broker - Turner Pope
377 Investments
Rod.Hinchcliffe@mcpartners.com.au Andy Thacker
Zoe Alexander
+44 203 657 0050
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
bio-pharma company developing and supplying affordable standardised
phytocannabinoid derived medicines to patients globally. The
Company's founders were key figures in the global medical cannabis
industry and the core business strategy is to develop and supply
high quality phytocannabinoid derived medicines for the growing
demand in the medical markets in Europe, North America and
Australasia. MGC Pharma has a robust product offering targeting two
widespread medical conditions - epilepsy and dementia - and has
further products in the development pipeline. The most advanced of
these is ArtemiC(TM) , which recently successfully completed Phase
II trials as a potential aid to the recovery of moderate COVID-19
patients.
Employing its 'Nature to Medicine' strategy, MGC Pharma has
partnered with renowned institutions and academia to optimise
cultivation and the development of targeted phytocannabinoid
derived medicines products prior to production in the Company's
EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world
renowned academic institutions, and including recent research
highlighting the positive impact of using specific phytocannabinoid
formulations developed by MGC Pharma in the treatment of
glioblastoma, the most aggressive and so far therapeutically
resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK,
Brazil and Ireland and has a global distribution footprint via an
extensive network of commercial partners meaning that it is poised
to supply the global market.
Follow us through our social media channels :
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFIFEDFDIAIIL
(END) Dow Jones Newswires
February 09, 2021 03:02 ET (08:02 GMT)
Grafico Azioni MGC Pharmaceuticals (ASX:MXC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni MGC Pharmaceuticals (ASX:MXC)
Storico
Da Apr 2023 a Apr 2024